Trial Profile
A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2019
Price :
$35
*
At a glance
- Drugs Atesidorsen (Primary)
- Indications Acromegaly
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Antisense Therapeutics
- 01 Aug 2018 Results published in the European Journal of Endocrinology
- 24 May 2018 Results presented in an Antisense Therapeutics media release.
- 24 May 2018 Reduction in serum insulin-like growth factor-I (sIGF-1) levels from baseline at week 14, according to an Antisense Therapeutics media release